KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
KORU Medical Systems (NASDAQ: KRMD) has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, where management will discuss financial results and provide a corporate update.
The conference call will be accessible via phone for U.S. and Canadian participants at (877)-407-0784, and international callers at (201)-689-8560. A live and archived webcast will be available on the company's investor relations website for six months.
KORU Medical Systems (NASDAQ: KRMD) ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 mercoledì 12 marzo 2025. L'azienda terrà una conferenza telefonica e una trasmissione in diretta alle 16:30 ET dello stesso giorno, durante la quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento aziendale.
La conferenza telefonica sarà accessibile tramite telefono per i partecipanti degli Stati Uniti e del Canada al numero (877)-407-0784, e per i chiamanti internazionali al numero (201)-689-8560. Una trasmissione in diretta e registrata sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda per sei mesi.
KORU Medical Systems (NASDAQ: KRMD) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el miércoles 12 de marzo de 2025. La empresa llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 p.m. ET del mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización corporativa.
La conferencia telefónica será accesible por teléfono para los participantes de EE. UU. y Canadá al (877)-407-0784, y para los llamadores internacionales al (201)-689-8560. Una transmisión en vivo y grabada estará disponible en el sitio web de relaciones con inversores de la empresa durante seis meses.
KORU Medical Systems (NASDAQ: KRMD)는 2024년 4분기 및 연간 재무 결과를 2025년 3월 12일 수요일에 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜 및 웹캐스트를 개최하며, 경영진은 재무 결과를 논의하고 기업 업데이트를 제공할 예정입니다.
컨퍼런스 콜은 미국 및 캐나다 참가자를 위해 전화로 (877)-407-0784로, 국제 전화 참가자는 (201)-689-8560으로 접근할 수 있습니다. 실시간 및 기록된 웹캐스트는 회사의 투자자 관계 웹사이트에서 6개월 동안 제공됩니다.
KORU Medical Systems (NASDAQ: KRMD) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le mercredi 12 mars 2025. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 16h30 ET, où la direction discutera des résultats financiers et fournira une mise à jour de l'entreprise.
La conférence téléphonique sera accessible par téléphone pour les participants américains et canadiens au (877)-407-0784, et pour les appelants internationaux au (201)-689-8560. Un webinaire en direct et archivé sera disponible sur le site web des relations investisseurs de l'entreprise pendant six mois.
KORU Medical Systems (NASDAQ: KRMD) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Mittwoch, den 12. März 2025, veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, in dem das Management die Finanzergebnisse diskutiert und ein Unternehmensupdate gibt.
Die Telefonkonferenz ist für Teilnehmer aus den USA und Kanada unter (877)-407-0784 und für internationale Anrufer unter (201)-689-8560 zugänglich. Ein Live- und Archiv-Webcast wird auf der Website der Investor Relations des Unternehmens für sechs Monate verfügbar sein.
- None.
- None.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877)-407-0784 for participants in the
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219838224/en/
Investor Contact:
Louisa Smith
investor@korumedical.com
Source: KORU Medical Systems, Inc.
FAQ
When will KORU Medical Systems (KRMD) release Q4 and full year 2024 earnings?
What time is KRMD's Q4 2024 earnings call?
How can investors access KRMD's Q4 2024 earnings call?
How long will KRMD's Q4 2024 earnings webcast be available?
